Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CTKB

CTKB - Cytek Biosciences, Inc. Stock Price, Fair Value and News

$4.01+0.01 (+0.25%)
Market Closed

40/100

CTKB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

40/100

CTKB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CTKB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CTKB Price Action

Last 7 days

-5.0%

Last 30 days

-8.0%

Last 90 days

-17.5%

Trailing 12 Months

-3.1%

CTKB RSI Chart

CTKB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CTKB Valuation

Market Cap

515.5M

Price/Earnings (Trailing)

-7.75

Price/Sales (Trailing)

2.56

EV/EBITDA

-19.07

Price/Free Cashflow

-58.78

CTKB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CTKB Fundamentals

CTKB Revenue

Revenue (TTM)

201.5M

Rev. Growth (Yr)

8.12%

Rev. Growth (Qtr)

18.83%

CTKB Earnings

Earnings (TTM)

-66.5M

Earnings Growth (Yr)

-557.1%

Earnings Growth (Qtr)

-704.6%

CTKB Profitability

EBT Margin

-14.81%

Return on Equity

-19.47%

Return on Assets

-14.42%

Free Cashflow Yield

-1.7%

CTKB Investor Care

Shares Dilution (1Y)

0.35%

CTKB Alerts

  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025197.1M196.0M196.8M201.5M
2024200.8M197.7M201.2M200.5M
2023166.1M175.6M183.1M193.0M
2022138.7M148.5M154.6M164.0M
2021101.6M110.4M119.2M128.0M
202000092.8M
Get all data in R, Python etc through our Historical Stock Data APIs

About Cytek Biosciences, Inc.

CTKB
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
 CEO
 WEBSITEhttps://cytekbio.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES699

Cytek Biosciences, Inc. Frequently Asked Questions

CTKB is the stock ticker symbol of Cytek Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Cytek Biosciences, Inc. is 515.49 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, CTKB's PE ratio (Price to Earnings) is -7.75 and Price to Sales (PS) ratio is 2.56. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CTKB PE ratio will change depending on the future growth rate expectations of investors.